Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
Manic/Hypomanic Symptom Burden and Cardiovascular Mortality in Bipolar Disorder
Psychosomatic Medicine, 07/01/09
Fiedorowicz JG et al. - Participants with bipolar I disorder may face a greater risk of cardiovascular mortality than those with bipolar II disorder. This difference in cardiovascular mortality risk may reflect manic/hypomanic symptom burden.
Methods- Participants with major affective disorders were recruited for the National Institute of Mental Health Collaborative Depression Study and followed prospectively for up to 25 years.
- A total of 435 participants met the diagnostic criteria for bipolar I (n = 288) or bipolar II (n = 147) disorder based on Research Diagnostic Criteria at intake and measures of psychiatric symptoms during follow-up.
- Diagnostic subtypes were contrasted by cardiovascular mortality risk using Cox proportional hazards regression.
- Affective symptom burden (the proportion of time with clinically significant manic/hypomanic or depressive symptoms) and treatment exposure were additionally included in the models.
- Thirty-three participants died from cardiovascular causes.
- Participants with bipolar I disorder had more than double the cardiovascular mortality risk of those with bipolar II disorder, after controlling for age and gender (hazard ratio = 2.35, 95% Confidence Interval = 1.04–5.33; p = .04).
- The observed difference in cardiovascular mortality between these subtypes was at least partially confounded by the burden of clinically significant manic/hypomanic symptoms which predicted cardiovascular mortality independent of diagnosis, treatment exposure, age, gender, and cardiovascular risk factors at intake.
- Selective serotonin uptake inhibitors seemed protective although they were introduced late in follow-up. Depressive symptom burden was not related to cardiovascular mortality.
Today in Anxiety...keeping you current
Receive free subspecialty "5-minute updates" via email
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
An algorithm for the pharmacological treatment of depression
Acta Psychiatrica Scandinavica, 11/04/09
How adolescents who cut themselves differ from those who take overdoses
European Child and Adolescent Psychiatry, 10/05/09
Today in Mood Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Management of agitation and aggression associated with Alzheimers disease: controversies and possible solutions
Current Opinion in Psychiatry, 10/12/09
Does Dual Antidepressant Therapy as Initial Treatment Hasten and Increase Remission from Depression
Journal of Psychiatric Practice, 09/29/09
Today in Neuro/Psych Pharmacol...keeping you current
Receive free subspecialty "5-minute updates" via email
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Does Dual Antidepressant Therapy as Initial Treatment Hasten and Increase Remission from Depression
Journal of Psychiatric Practice, 09/29/09
Today in Neuropsych Sciences...keeping you current
Receive free subspecialty "5-minute updates" via email
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia
Journal of Psychopharmacology, 10/19/09
Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism
Journal of Psychopharmacology, 10/20/09
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
Clinical Interventions in Aging, 09/29/09
Sponsor
Article Search
Sponsor


See Latest Articles


